Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis

被引:57
作者
Halsall, JA [1 ]
Osborne, JE
Pringle, JH
Hutchinson, PE
机构
[1] Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE2 7LX, Leics, England
[2] Leicester Royal Infirm, Dept Dermatol, Leicester, Leics, England
关键词
psoriasis susceptibility; psoriasis treatment; VDR; VDR polymorphisms;
D O I
10.1097/01213011-200505000-00011
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Psoriasis is a genetically determined disease characterized by hype rpro I iferati on and disordered maturation of the epidermis. Th1 lymphocytes are implicated in its pathogenesis. The vitamin D receptor (VDR) is a candidate modifying gene, having immunosuppressive effects and being involved in anti-proliferative and pro-differentiation pathways in keratinocytes. There is suggestive evidence that the A allele of the A-1012G polymorphism is associated with down-regulation of the Th1 response, via GATA-3. The F and T alleles of Fok1 and Taq1 have been associated with increased VDR activity. The present study aimed to test the hypothesis that the A allele of A-1012G is protective for occurrence and severity of psoriasis and enhances therapeutic response to vitamin D analogues and that these effects would be additive to those of Fok1 and Taq1. The study group comprised 206 psoriasis patients who had received topical calcipotriol treatment and 80 controls. There was no significant linkage disequilibrium between any pair of the three polymorphic sites (P=0.3-0.8). The A, F and T alleles were positively associated with calcipotriol response: AA genotype (compared to AG/GG), odds ratio (OR)=2.18 (P=0.04); TT, OR=1.97 (P=0.03); AAFF genotype combination, OR=4.11 (P=0.03); AATT, OR=5.64 (P=0.005); and FFTT, OR=3.22 (P=0.01). Comparing patients without, to patients with, a family history of psoriasis, the A allele was under represented (P=0.01) and the AAFF genotype combination even more so (compared to residual genotypes) (OR= 0.24; P=0.005). AAFF was also under-represented in patients without a family history compared to controls (OR=0.31; P=0.04). There were no associations of family history with Fok1 and Taq1. There were no associations of severity of psoriasis with any polymorphism. In conclusion, the A-1012G, Fok1 and Taq1 VDR polymorphisms were associated with response to calcipotriol. A-1012G and Fok1 were associated with susceptibility to non-familial psoriasis. (c) 2005 Lippincott Williams & Wilkins.
引用
收藏
页码:349 / 355
页数:7
相关论文
共 50 条
[1]   Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis [J].
Ahnini, RT ;
Camp, NJ ;
Cork, MJ ;
Mee, JB ;
Keohane, SG ;
Duff, GW ;
di Giovine, FS .
HUMAN MOLECULAR GENETICS, 1999, 8 (06) :1135-1140
[2]  
Allen M, 2003, AM J HUM GENET, V73, P430
[3]  
ALROY I, 1995, MOL CELL BIOL, V15, P5789
[4]  
[Anonymous], 2000, ARLEQUIN SOFTWARE PO
[5]   A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele [J].
Asumalahti, K ;
Laitinen, T ;
Itkonen-Vatjus, R ;
Lokki, ML ;
Suomela, S ;
Snellman, E ;
Saarialho-Kere, U ;
Kere, J .
HUMAN MOLECULAR GENETICS, 2000, 9 (10) :1533-1542
[6]   The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-γ, interleukin-2, and tumor necrosis factor-α, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations:: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients [J].
Austin, LM ;
Ozawa, M ;
Kikuchi, T ;
Walters, IB ;
Krueger, JG .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (05) :752-759
[7]   The genetics of psoriasis, psoriatic arthritis and atopic dermatitis [J].
Bowcock, AM ;
Cookson, WOCM .
HUMAN MOLECULAR GENETICS, 2004, 13 :R43-R55
[8]   Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D-3 [J].
Chen, ML ;
Perez, A ;
Sanan, DK ;
Heinrich, G ;
Chen, TC ;
Holick, MF .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (04) :637-641
[9]  
Cippitelli M, 1998, EUR J IMMUNOL, V28, P3017, DOI 10.1002/(SICI)1521-4141(199810)28:10<3017::AID-IMMU3017>3.3.CO
[10]  
2-Y